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Abstract
Metabolic syndrome is a global public health problem and predisposes individuals to 
obesity, diabetes and cardiovascular disease. Although the underlying mechanisms 
remain to be elucidated, accumulating evidence has uncovered a critical role of 
adipokines. Chemerin, encoded by the gene Rarres2, is a newly discovered adipokine 
involved in inflammation, adipogenesis, angiogenesis and energy metabolism. In 
humans, local and circulating levels of chemerin are positively correlated with BMI 
and obesity-related biomarkers. In this review, we discuss both peripheral and central 
roles of chemerin in regulating body metabolism. In general, chemerin is upregulated 
in obese and diabetic animals. Previous studies by gain or loss of function show an 
association of chemerin with adipogenesis, glucose homeostasis, food intake and 
body weight. In the brain, the hypothalamus integrates peripheral afferent signals 
including adipokines to regulate appetite and energy homeostasis. Chemerin increases 
food intake in seasonal animals by acting on hypothalamic stem cells, the tanycytes. In 
peripheral tissues, chemerin increases cell expansion, inflammation and angiogenesis 
in adipose tissue, collectively resulting in adiposity. While chemerin signalling enhances 
insulin secretion from pancreatic islets, contradictory results have been reported on 
how chemerin links to obesity and insulin resistance. Given the association of chemerin 
with obesity comorbidities in humans, advances in translational research targeting 
chemerin are expected to mitigate metabolic disorders. Together, the exciting findings 
gathered in the last decade clearly indicate a crucial multifaceted role for chemerin in 
the regulation of energy balance, making it a promising candidate for urgently needed 
pharmacological treatment strategies for obesity.
Introduction
Adipokines, secreted by adipose tissue, are involved in 
the pathogenesis of metabolic syndrome (Lehr  et  al. 
2012). Chemerin, encoded by the gene retinoic acid 
receptor responder 2 (Rarres2), also known as tazarotene-
induced gene 2 (TIG2), was recently identified as one 
of the adipokines with autocrine, paracrine and even 
endocrine roles in vivo (Rourke et al. 2013). Chemerin is 
an inflammatory chemokine and was originally 
discovered as a novel retinoic acid-responsive gene in 
psoriatic skin lesions, implying an immunomodulating 
role (Nagpal  et al. 1997). Initially, chemerin was termed 
TIG2 because an increased expression was reported after 
treatment of skin raft cultures with tazarotone, a synthetic 
retinoid (Nagpal et al. 1997). It was further characterised as 
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a retinoid-responsive gene and thereby called retinoic acid 
receptor responder 2 (Rarres2). Retinoic acid responsiveness 
of chemerin was later confirmed in various tissues and 
cells (Nagpal et al. 1997, Martensson et al. 2005, Gonzalvo-
Feo et al. 2014, Helfer et al. 2016). Further studies revealed 
that chemerin was highly expressed in white adipose 
tissue (WAT), liver and lung while its receptor CMKLR1 is 
predominantly expressed in adipocyte and immune cells 
(Bozaoglu et al. 2007, Goralski et al. 2007). In mammalian 
cells, chemerin is initially synthesised as a 163 amino 
acid (aa) proprecursor. The N-terminal truncation of 
20 aa signal peptide results in the release of inactive 
precursor (chemerin-S163) into extracellular niches 
or circulation system (Fig.  1A). The precursor requires 
further extracellular C-terminal cleavage at various sites 
to generate active and deactivated chemerin. For example, 
the proteolytic cleavage at its C-terminus by plasmin, 
elastase and cathepsin G activates chemerin and generates 
various isoforms (chemerin-K158, -S157 and -F156) with 
different affinity to CMKLR1 (Fig.  1B and C). Further 
cleavage of bioactive chemerin by chymase produces 
chemerin-F154 and terminates its activity (Mattern et al. 
2014). Thus, the C-terminal proteolytic processing serves 
as a key regulatory mechanism to determine the local and 
systemic concentration of active chemerin. To date, eight 
serine proteases have been identified to C-terminally 
process chemerin and its precursor in vitro. These serine 
proteases are generally secreted into extracellular matrix or 
blood plasma to exert their biological effect (Mattern et al. 
2014).
After secretion, chemerin precursor is processed 
by various extracellular proteases of the coagulation, 
fibrinolytic and inflammatory cascades, which are 
differentially expressed in a wide range of tissues 
and thereby produce distinct chemerin isoforms. 
Although inert chemerin precursor is the dominant 
isoform in plasma from healthy humans, differential 
chemerin isoforms in human blood (chemerin-A155, 
-S157 and -K158), cerebrospinal fluid (chemerin-K158), 
ascites (chemerin-S157), hemofiltrate (chemerin-F154) 
and synovial fluid (chemerin-K158) under inflammatory 
conditions have been detected (Rourke  et  al. 2014). 
Results from mass spectrometry analysis indicate that 
bioactive chemerin generation takes place at early stages 
of inflammation (Wittamer  et  al. 2005). ELISAs using 
antibodies raised against C-terminal peptides have 
shown that Chemerin-K158 is the dominant isoform in 
the synovial fluid of patients with arthritis (Zhao  et  al. 
2011). Further analysis reveals that the fraction of 
bioactive chemerin is much higher in the inflammatory 
cerebrospinal fluid and synovial fluid from patients than 
the plasma from healthy volunteers (Zhao  et  al. 2011). 
In the adipose tissue of patients with obesity, chemerin 
isoforms display a different profile from plasma, with 
minimal chemerin precursor and significant levels of 
bioactive chemerin-S157 (Chang  et  al. 2016). These 
results suggest that complex chemerin processing occurs 
in vivo, especially during inflammation. Mass spectrometry 
analysis is required to determine the profile of chemerin 
isoforms in other parenchymal tissues such as liver 
and lung.
Chemerin has been shown to display various roles 
in the pathogenesis of inflammatory and metabolic 
disease in multiple organs such as adipose tissue, lung, 
skin, cardiovascular system, reproductive tract, digestive 
tract, skeleton and joints. The biological function of 
chemerin as pro- or anti-inflammatory modulators 
remains controversial. At the onset of inflammatory 
reaction, polymorphonuclear cells are firstly recruited to 
the damaged sites, where they promote the generation 
Figure 1
Processing of prochemerin. (A) The scheme 
describes the release of preprochemerin (1), 
proteolysis of prochemerin (2) into bioactive 
chemerin (3) and transformation of active isoform 
into deactivated chemerin (4). (B) The predicted 
3D structure of chemerin from RaptorX structure 
prediction server. (C) The processing of 
prochemerin by various proteases.
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of bioactive chemerin by releasing proteases including 
elastase and cathepsin G into the milieu (Wittamer et al. 
2003, 2005). Subsequently, chemerin functions to 
enhance the chemotaxis of immature dendritic cells and 
macrophages, bridging innate and adaptive immunity for 
the initiation of immune response. In contrast, chemerin 
treatment reduces the recruitment of neutrophil 
and macrophages to the inflammatory sites and the 
expression of proinflammatory cytokine (Cash et al. 2008, 
Luangsay et al. 2009). These studies suggest that chemerin 
acts as either a proinflammatory or anti-inflammatory 
modulator depending on the biological systems. A 
fundamental switch in our understanding of chemerin’s 
function occurred in 2007 when chemerin was found to be 
highly expressed in WAT (Goralski et al. 2007). Subsequent 
studies revealed that chemerin acts on its receptor CMKLR1 
to affect adipogenesis, angiogenesis and inflammation in 
adipose tissue. Beyond the lipid metabolism, chemerin 
also influences the dysregulation of glucose metabolism. 
Supporting the important roles of chemerin in systemic 
lipid and glucose metabolism, accumulating clinical 
data indicate that local and/or circulating chemerin 
levels are increased in patients with obesity, diabetes and 
cardiovascular disease (Perumalsamy  et  al. 2017). Given 
the scope of this review, we are focusing exclusively on 
the role of chemerin in regulating metabolism.
Chemerin and its receptors
As a chemoattractant protein, chemerin was first identified 
as the natural ligand for the G-protein-coupled receptor 
CMKLR1, also known as ChemR23 (Meder  et  al. 2003, 
Wittamer  et  al. 2003). Later, owing to a high sequence 
identity, chemerin was also recognised as the ligand for 
another G protein-coupled receptor GPR1 (Barnea  et  al. 
2008, Southern et al. 2013, Rourke et al. 2014). The third 
chemerin receptor chemokine (C-C motif) receptor-like 2 
(Ccrl2) was identified in experiments based on binding 
assays (Zabel  et  al. 2008). Recently, De Henau  et  al. 
generated cell lines expressing each individual chemerin 
receptor and compared their binding and signalling 
properties separately of cellular context. Chemerin binds 
to both CMKLR1 and GPR1 with similar affinity, but lower 
affinity to CCRL2 (De Henau et al. 2016).
Chemerin receptor signalling has been reviewed 
in detail recently (Mattern  et  al. 2014, Kennedy & 
Davenport 2018) and therefore we only provide a short 
summary here before we discuss the role of chemerin 
and its receptors in energy balance regulation. Chemerin 
receptors display cell-specific expression profiles, thus 
making a comparison of receptor activation in the same 
tissue difficult (Kennedy & Davenport 2018). CMKLR1 
expression is wide-spread in different organs and 
tissues. It is expressed in the adaptive immune system, 
with high level of transcripts detected in macrophages, 
natural killer cells, immature dendritic cells and 
leucocytes (Samson  et  al. 1998, Wittamer  et  al. 2003, 
Vermi  et  al. 2005, Parolini  et  al. 2007). Additionally, 
it has been detected in the cardiovascular system 
(including smooth muscle cells, endothelial cells and 
cardiomyocytes), the reproductive system (such as 
Leydig cells) and the skin (Li  et  al. 2014, Banas  et  al. 
2015, Kennedy et al. 2016). In line with chemerin’s role 
as an adipokine, CMKLR1 is expressed in adipocytes, 
with higher levels in white compared to brown adipose 
tissue (BAT) (Goralski et al. 2007). In the brain, CMKLR1 
is found in microglia of the hippocampus as well as 
ependymal cells and tanycytes lining the third ventricle 
of the hypothalamus (Guo  et  al. 2012, Helfer  et  al. 
2016). CMKLR1 is a Gi/o-protein-coupled receptor 
that signals through mitogen-activated protein kinase 
(MAPK), extracellular signal-regulated kinases (ERK) 
and phosphatidylinositol 3 kinase (PI3K)-AKT pathways 
to regulate biological functions such as angiogenesis 
and inflammation (Wittamer et al. 2003, Goralski et al. 
2007, Sell et al. 2009, De Henau et al. 2016).
GPR1 is predominantly expressed in central 
nervous system, such as glioblastoma cells, brain-
derived fibroblast-like cells lines and microglia although 
expression was also reported in skin cells, white 
adipocytes, Leydig cells and granulosa cells (Edinger et al. 
1998, Shimizu  et  al. 1999, Reverchon  et  al. 2012, 
Li  et  al. 2014, Banas  et  al. 2015). Limited studies have 
investigated signalling transduction properties of GPR1 
upon activation of chemerin. As with CMKLR1, GPR1 
activates ERK1/2-MAPK pathways (Rourke et al. 2015, De 
Henau  et  al. 2016). Furthermore, binding of chemerin 
to CMKLR1 and GPR1 promotes RhoA/ROCK-dependent 
pathways (Rourke et al. 2015).
Unlike CMKLR1 and GPR1, the binding of chemerin 
to CCRL2 does not induce downstream signalling 
pathways, calcium mobilisation or ligand internalisation, 
and it is therefore designated as an atypical, silent or non-
signalling chemokine receptor. CCRL2 seems to have 
the ability to amplify local chemerin concentration for 
CMKLR1 interaction (Zabel  et  al. 2008, De Henau  et  al. 
2016).
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The role of chemerin in energy balance 
regulation and obesity
Effect on whole body metabolism
After the discovery of leptin, adipokines have been 
increasingly found to have many effects on biological 
functions including blood pressure, homeostasis, 
adipogenesis and glucose metabolism linking adipokines 
to the metabolic syndrome. Several studies have suggested 
that the adipokine chemerin plays a crucial role in 
adipogenesis, and this has been implicated in the control 
of adipose tissue in regard to the regulation of glucose 
homeostasis and the development of obesity.
In general, contradictory results have been reported 
on what role chemerin plays in whole body metabolism 
and how it links to obesity and insulin resistance. 
Initially, studies in humans indicated that chemerin 
gene expression and circulating levels are positively 
correlated with increased BMI and obesity-related 
biomarkers (Bozaoglu  et  al. 2007, 2009, Sell  et  al. 2009, 
Chakaroun et al. 2012). In support, plasma chemerin levels 
are increased in diet-induced obese mice and reduced by 
overnight fasting. This effect is independent of the strain 
of mice (FVB and C57BL/6) used (Wargent et al. 2015). In 
contrast, there was no change of plasma chemerin levels 
in NMRI mice on a high-fat or cafeteria diet (Hansen et al. 
2014). This discrepancy might be explained by different 
strains of mice being more susceptible to diet-induced 
obesity than others. Plasma chemerin levels were raised in 
genetically obese (ob/ob) mice (Ernst et al. 2010), whereas 
leptin receptor-deficient mice (db/db mice) had decreased 
levels of serum chemerin concentration and displayed an 
increase in insulin signalling (Takahashi  et  al. 2008). In 
rats maintained on a restricted diet, a decrease in the level 
of chemerin (Rarres2) mRNA in the WAT was associated 
with a decrease of serum chemerin concentration. When 
these rats were re-fed after diet restriction, both chemerin 
expression in WAT and serum chemerin concentration 
were upregulated (Stelmanska  et  al. 2013). Surprisingly, 
intraperitoneal injections of chemerin into rats resulted 
in a lower body weight (Brunetti et al. 2014). This seems 
to contradict the notion that raised plasma chemerin 
levels promote obesity. Our study using chemerin 
injections directly into the brain suggested that there 
is a bimodal response on body weight and food intake. 
Acute intracerebroventricular bolus injection of chemerin 
decreased body weight while chronic chemerin infusion 
increased body weight (Helfer et al. 2016). Thus, chemerin 
might exert different biological actions depending on the 
timeframe investigated.
Given that most studies report increased chemerin 
levels with increased body weight, a long-term 
proinflammatory effect might link it to insulin resistance 
in obesity. While intraperitoneal injections of chemerin 
into normal mice had no effect on glucose tolerance, 
there was increased glucose intolerance in ob/ob mice 
and db/db mice (Ernst  et  al. 2010). Further indications 
linking chemerin with glucose homeostasis were provided 
by studies using mice lacking the GPR1 receptor. Gpr1-
knockout mice on a high-fat diet showed increased glucose 
intolerance compared to wild-type mice, but displayed no 
change in body weight, body composition and energy 
expenditure (Rourke et al. 2014) (explained in detail later).
Similarly, studies using Cmkrl1-knockout mice have 
reported inconsistent metabolic phenotypes. Cmklr1-
knockout mice have reduced food intake and body weight 
compared to wild-type mice when fed on either a low- or 
a high-fat diet (Ernst  et al. 2012) but other studies have 
found no or little effect on body composition and glucose 
homeostasis (Rouger et al. 2013, Gruben et al. 2014). The 
differences reported might have been due to age and sex 
of the mice and different lengths and diets used in these 
studies. Recently, Wargent et al. have attempted to clarify 
the situation and found that male and female Cmklr1-
knockout mice on a high-fat diet have mildly increased 
body fat and impaired glucose homeostasis, although this 
is age dependent (Wargent et al. 2015). Thus, it is unclear 
whether raised chemerin levels promote obesity and more 
studies are needed to provide a definite answer.
Effect on the brain
Chemerin and its receptors are localised in distinct 
brain regions indicating a potential central role. In 
mice and rats, chemerin (Rarres2) mRNA is expressed 
in the hypothalamus (Miranda-Angulo  et  al. 2014, 
Helfer  et  al. 2016). In rats, Cmklr1 transcript was found 
in the prefrontal cortex, hippocampus, cerebellum and 
hypothalamus (Guo et al. 2012, Helfer et al. 2016). Both 
CMKLR1 and GPR1 are highly expressed in the mouse 
brain, but the tissue specificity has not been identified 
among different brain regions (Rourke  et  al. 2014). 
Although it has been reported that hypothalamic nuclei 
express Gpr1 in particularly high levels, Gpr1 mRNA were 
not found to be expressed in the rat hypothalamus using 
in situ hybridisation (Helfer et al. 2016). In GPR1 knockout 
mice, chemerin (Rarres2) mRNA expression is increased 
in the hypothalamus, whereas CMKLR1 expression is 
simultaneously decreased in the cortex and hypothalamus 
(Fig. 2A) (Rourke et al. 2014).
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Given the important role of chemerin in energy 
balance regulation and obesity, surprisingly little is known 
about its expression and function in the hypothalamus, 
the key area of energy balance regulation. In the brain, 
the hypothalamus is critical in sensing and integrating 
peripheral signals such as adipokines (Coll & Yeo 2013). 
In the hypothalamus of rats, chemerin and Cmklr1 (but 
not Gpr1) transcripts were localised in the ependymal 
cells and tanycytes, specialised glial cells lining the 
third ventricle and extending into the arcuate nucleus, 
hypothalamic areas closely associated with homeostatic 
appetite regulation. The third chemerin receptor CCRL2 
was also found in the same hypothalamic loci, possibly 
increasing the local chemerin signal (Helfer et al. 2016). In 
contrast, in mice, chemerin is predominantly expressed 
in ependymal cells but not in the tanycytes (Miranda-
Angulo et al. 2014). The observation that chemerin is not 
expressed uniformly in the hypothalamus might suggest 
that it plays different roles in different locations (Fig. 2A); 
however, a potential species-specific expression pattern 
needs to be confirmed in further studies.
An initial link between chemerin and appetite 
and body weight regulation in the hypothalamus was 
identified in genome-wide expression analysis (Ross et al. 
2011). Further investigations identified chemerin as 
downstream target of retinoic acid signalling in the 
hypothalamus in photoperiod-sensitive F344 rats 
(Fig.  2B). Intracerebroventricular injections of all-trans 
retionic acid into the third ventricle of F344 rats increased 
chemerin mRNA expression in ependymal cells and 
tanycytes lining the third ventricle (Helfer  et  al. 2016). 
Photoperiod-sensitive mammals can be stimulated to 
make marked physiological changes in body weight 
and food intake status simply by changing photoperiod 
(daylength); thus, they are used as a natural model of 
obesity (Ebling 2014). While laboratory rats are generally 
not responsive to photoperiod, the F344 rat is one of the 
few rat strains that retained its photoperiod sensitivity 
and undergoes pronounced cycles of weight gain and 
weight loss under different photoperiod conditions 
(Tavolaro et al. 2015). In the hypothalamus of F344 rats, 
chemerin is strongly regulated by photoperiodic changes. 
Furthermore, intracerebroventricular administration of 
chemerin into F344 rats alters food intake and body weight 
with associated changes in hypothalamic neuropeptides 
involved in feeding and growth (Fig.  2C). However, in 
Figure 2
The expression, signalling and function of chemerin in the hypothalamus. (A) Chemerin, Cmklr1, Ccrl2 but not Gpr1 are expressed in the tanycytes and 
ependymal cells lining the third ventricle of the hypothalamus of F344 rats (Helfer et al. 2016). In C57BL/6 mice, chemerin expression is restricted to 
ependymal cells (Miranda-Angulo et al. 2014). (B) In tanycytes, chemerin is downstream of retinoic acid signalling. Retinol enters the tanycytes where it 
is synthesised to retinoic acid (RA). RA enters the nucleus and binding to its receptors RAR and RXR leads to transcription of Rarres2, which is translated 
into chemerin. Chemerin binds to its receptor CMKLR1 and activates its downstream signalling pathway in an autocrine or paracrine manner. (C) In 
general, long-term application of chemerin increases food intake and loss of function reduces food intake, although contradictory results have been 
reported.
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F344 rats, this response is transient and not sustained over 
long term (Helfer et al. 2016). To investigate the role that 
chemerin plays, not only in mediating a photoperiodic 
response, but also as a gateway for a feedback signal from 
the periphery to the hypothamus, the results in the F344 
rat need to be confirmed in non-seasonal animals. To 
this date, a study in Sprague–Dawley rats has reported 
that acute injection of chemerin into the arcuate nucleus 
of the hypothalamus has no effect on food intake and 
body weight nor the expression of appetite-regulating 
neuropeptides. This negative result may be explained by 
the dose of chemerin and the injection site used in this 
study (Brunetti et al. 2011). Later, the same authors used 
peripheral chemerin injections and showed a reduction in 
food intake and body weight, but this seemed to have only 
a minor effect on hypothalamic neuropeptide expression 
(Brunetti et al. 2014).
While these studies showed seemingly contradictory 
responses due to different routes, mode of delivery and 
doses used, the results indicate that chemerin might not 
act directly through known neuroendocrine appetite-
regulating pathways to exert its effects. This idea is 
supported by the finding that mice lacking CMKLR1 show 
reduced food intake and body weight but no changes 
in hypothalamic neuropeptides (Ernst  et  al. 2012). An 
exciting further possibility is that chemerin might play 
a role in hypothalamic cellular remodelling. Central 
chemerin administration (acute and chronic) increases 
expression of vimentin, an intermediate filament protein, 
which is used as a marker for visualising cells of glial origin 
such as ependymal cells and tanycytes. Additionally, long-
term central chemerin infusion results in morphological 
changes to the hypothalamus by increasing vimentin 
immunolabelling of tanycytes (Helfer et al. 2016). These 
results suggest that chemerin plays a pivotal part in 
hypothalamic remodelling driving long-term changes 
in body weight and food intake regulation. Together, 
the studies highlight a critical role for chemerin in the 
neuroendocrine control of energy metabolism. Further 
studies are necessary to understand how the hypothalamus 
integrates chemerin signal and will provide new insights 
into the physiological basis of appetite regulation.
It is interesting to note that independent of a 
neuroendocrine role of chemerin, Cmklr1 mRNA has 
recently been shown to be upregulated in Alzheimer 
patients and in mice, it was identified as a receptor for 
amyloid-β peptides suggesting a potential role of chemerin 
in the progression of Alzheimer’s disease (Peng et al. 2015). 
Additionally, CMKLR1 expression in the hippocampus 
and prefrontal cortex of rats was recently linked with 
depression (Guo et al. 2012), possibly through activation 
by resolvins (Deyama et al. 2018) adding yet another level 
of complexity to the biological role of chemerin. Thus 
chemerin–CMKLR1 interaction in the brain remains a 
fascinating avenue for further research.
Effect on adiposity
Adiposity is a condition of morbid overweight. Without 
using body weight, adiposity indexes that include the 
waist circumference indicate the amount of WAT, a strong 
predictor of metabolic disorder in humans (Bergman et al. 
2011). The white fat tissue per se releases a plethora of 
adipokines including chemerin to affect adipose tissue 
homeostasis, adipocyte metabolism and inflammation in 
fat tissue (Fig. 3). Chemerin and Cmklr1 are expressed at high 
levels in WAT but only in low levels in BAT (Goralski et al. 
2007). BAT is associated with thermogenesis; hence, this 
would suggest that chemerin exerts its effect on weight 
by regulating adipogenesis rather than thermogenesis. 
However, recently, it has been shown that loss of CMKLR1 
suppresses the expression of thermogenesis-related genes 
in WAT and BAT (Huang et al. 2016). Due to its capability 
to produce heat instead of ATP resulting in weight loss, 
BAT has been identified as a potential target for treatment 
of obesity. Retinoic acid is a key player in the regulation 
of thermogenesis of BAT (Okla  et  al. 2017). Given that 
chemerin is downstream of retinoic acid signalling, this 
raises the intriguing possibility that chemerin could 
promote BAT activity and/or browning of WAT.
Targeting adipocytes
Adiposity is featured by an excessive expansion of WAT 
that relies on an increase in adipocyte size (hypertrophic 
obesity) and adipocyte number (hyperplastic obesity) 
(Sun  et  al. 2011). During the differentiation of human 
preadipocytes into adipocytes, the expression of both 
chemerin and CMKLR1 is dramatically increased 
(Roh  et  al. 2007). The activation of chemerin-CMKLR1 
axis facilitates the proliferation and differentiation of 
preadipocytes by inducing the AKT-mTOR and ERK 
signalling cascade (Jiang  et  al. 2018). Interestingly, 
chemerin-CMKLR1 signalling, regulated by peroxisome 
proliferator-activated receptor γ (PPARγ), predisposes 
the differentiation of bone marrow mesenchymal stem 
cells (BMSCs) into adipocytes rather than osteoblasts 
(Muruganandan  et  al. 2011, 2017). Inactivation of 
chemerin-CMKLR1 signalling by genetic manipulation or 
neutralisation with antibodies shifts the adipogenic clonal 
expansion of BMSCs to osteoblastogenic differentiation 
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(Muruganandan  et  al. 2011, 2017). Chemerin treatment 
also alters the fate of myoblast cells from myogenesis 
to adipogenesis (Li  et  al. 2015). Consistent with these 
studies, disruption of Cmklr1 gene in vivo reduces the food 
intake, body mass and fat deposition of mice (Ernst et al. 
2012). In contrast, another more recent study showed 
that Cmklr1-knockout mice display mild obesity but 
normal adipocyte differentiation (Rouger  et  al. 2013). It 
is found that the number of adipocytes is not changed 
in the Cmklr1-null mice, but there is an increase in the 
lipid storage in each of adipocytes. Unexpectedly, the 
differentiation of preadipocytes into adipocytes in vitro is 
not altered by loss of CMKLR1 (Rouger et al. 2013). The 
conflicting data confound our understanding of the role 
of chemerin in regulating adipogenesis. It is worthwhile 
to determine whether sex, diet, genetic background and 
sanitary status of animals influence the body weight 
and fat deposition of Cmklr1-knockout mice, as well as 
whether the cell type and the culture condition affect the 
preadipocyte differentiation.
Targeting endothelial cells
Adipose tissue consists of adipocytes and vascular 
endothelial cells, which provide blood supply for the 
growth of adipocytes (Rupnick et al. 2002, Liu & Meydani 
2003, Cutchins  et  al. 2012). Remodelling of existing 
vascular networks and formation of new blood vessels via 
angiogenesis are required to supply more nutrients and 
oxygen to the expanding adipose tissue mass (Lijnen 2008). 
CMKLR1 is expressed in human endothelial cells and is 
upregulated by proinflammatory cytokines (Kaur  et  al. 
2010). Chemerin activates the key angiogenic pathways 
through PI3K-AKT and MAPK-ERK signalling and induces 
angiogenesis in vitro by promoting the proliferation, 
differentiation, capillary tube formation and migration of 
endothelial cells (Kaur et al. 2010). The effect of chemerin-
mediated activation of MAPK-ERK signalling cascade is 
dose dependent and the application of MEK1 inhibitor 
abolishes chemerin-induced angiogenesis (Bozaoglu et al. 
2010, Kaur  et  al. 2010, Neves  et  al. 2015). The high 
expression of chemerin has recently been associated 
with upregulation of vascular endothelial growth factor 
(VEGF) and tumour angiogenesis (Wang  et  al. 2014, 
Lin  et al. 2016). Concomitant with the enhancement of 
preadipocyte differentiation, chemerin overexpression 
upregulates VEGF that promotes vascular endothelial 
cell proliferation, differentiation and angiogenesis in 
the cultured cells. Moreover, the vascular intensity 
Figure 3
The multidimensional effect of chemerin on 
adiposity. Multiple roles of chemerin in regulating 
inflammation, hyperplasia and angiogenesis in 
white adipose tissue are summarised.
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in the fat pad is increased by the overexpression of 
chemerin (Jiang  et  al. 2018), suggesting that chemerin 
boosts angiogenic potential of fat tissues. A genome-
wide association study in human population implies that 
serum chemerin level is highly heritable and significantly 
associated with single nucleotide polymorphism in EIDL3 
gene, which has been known to regulate angiogenesis 
(Bozaoglu  et  al. 2010). Thus, the reciprocal interaction 
between adipocytes and vascular endothelial cells may 
form a positive feedback loop promoting adipogenesis 
and obesity.
Targeting immune cells
It has been widely accepted that increased adiposity is 
associated with chronic low-grade systemic inflammation 
(metainflammation) (Tam  et  al. 2010, Mraz & Haluzik 
2014, Catrysse & van Loo 2017). Beyond adipocytes and 
endothelial cells, adipose tissue contains a number of 
immune cells (Weisberg  et  al. 2003, DiSpirito & Mathis 
2015). CMKLR1 is expressed in numerous immune cells 
that accumulate in the obese adipose tissue, including 
plasmacytoid dendritic cells, myeloid dendritic cells, 
macrophages and natural killer cells (Zabel  et  al. 2005, 
2006, Parolini et al. 2007). Chemerin was first identified to 
promote the chemotaxis of immature dendritic cells and 
macrophages (Wittamer et al. 2003, 2005). A recent study 
confirmed that chemerin recruits circulating dendritic cells 
into visceral adipose tissue, wherein adipocyte-derived 
HMGB1 protein activates TLR9 in the dendritic cells and 
induces the secretion of type I interferons. Subsequently, 
interferons in turn ignite the proinflammatory response 
of macrophages (Ghosh  et  al. 2016). The initiation of 
local and systemic inflammation by the adipocyte–
immunocyte crosstalk significantly contributes to 
insulin resistance and obesity. However, whether and 
how the inflammation exacerbates adiposity remains 
unclear. Several studies support a role for macrophages in 
regulating adipocyte hyperplasia (Keophiphath et al. 2009, 
Zhang et al. 2013, Brown et al. 2014). One study reported 
that human preadipocytes exposed to the conditioned 
medium from activated macrophages exhibited profound 
remodelling of extracellular matrix (Keophiphath  et  al. 
2009). The alteration of extracellular microenvironment 
significantly increases the proliferation and migration 
of preadipocytes, which expands the pool of adipocyte 
progenitors and could increase the adipose tissue in 
obesity. Another observation is that the macrophages, 
accumulated around the foci of dying adipocytes, 
promotes recruitment, proliferation and differentiation of 
adipocyte progenitors by secreting osteopontin (Lee et al. 
2013). Macrophages have been shown to form crown-
like structure around dying adipocyte after high-fat diet 
feeding (Kim et al. 2014). Further experiments are required 
to determine whether macrophages drive the high-fat-
induced hyperplasia of adipocyte. Together, these studies 
suggest that chemerin may exacerbate the adiposity by 
recruiting immune cells to the adipose tissue.
Effect on glucose metabolism
Type 2 diabetes mellitus (T2DM) is a metabolic disorder 
featured by insulin resistance ensued by elevated blood 
glucose (hyperglycaemia). Increased serum chemerin 
that occurs with obesity is highly correlated with the 
development of T2DM in humans (Roman  et  al. 2012). 
Although there is consensus that chemerin regulates 
glucose homeostasis, its role in regulating glucose 
tolerance remains unclear owing to the contradictory 
results derived from various in vivo and in vitro studies. 
Given that the insulin signalling pathway is the hub to 
maintain glucose homeostasis by increasing the uptake of 
glucose into fat and muscle and reducing the production 
of glucose in the liver, here, we summarise the function 
of chemerin in regulating insulin secretion and sensitivity 
(Table 1).
Targeting insulin secretion
Both glucose-stimulated insulin secretion from pancreas 
and insulin-stimulated glucose uptake in peripheral 
tissues contribute to the proper regulation of glucose 
tolerance. Chemerin and its receptor CMKLR1 are also 
expressed in the β cells of the pancreas, implying their role 
in modulating insulin secretion (Takahashi  et  al. 2011). 
Indeed, chemerin and CMKLR1-knockout mice display 
reduced glucose-stimulated insulin release, while the gain-
of-function study using chemerin transgenic mice shows 
enhanced insulin secretion in glucose tolerance tests 
(Takahashi et al. 2011, Ernst et al. 2012). Mechanistically, 
loss of chemerin in mice downregulates the expression 
of transcription factor MAFA and its downstream target 
gene GLUT2, which serves as a sensor and transporter for 
glucose in pancreatic β cells and thereby promotes insulin 
secretion (Takahashi  et  al. 2011). It is thus speculated 
that declined expression of GLUT2 in the chemerin-
deficient β cells underlies the impaired glucose-stimulated 
insulin secretion. Interestingly, chronic overexpression 
of chemerin in low-density lipoprotein receptor (LDLR)-
knockout mice does not alter the circulating level of insulin 
(Becker et al. 2010), suggesting the existence of a crosstalk 
between GLUT2 and LDLR in β cells (Thedrez et al. 2016).
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The second receptor for chemerin, GPR1, binds 
chemerin with a similar affinity to CMKLR1 (De 
Henau  et  al. 2016). The GPR1-deficient mice display 
not only a mild reduction in glucose-stimulated insulin 
release but also a significant lower level of fasting serum 
insulin under high-fat dietary condition (Rourke  et  al. 
2014). Although previous studies provide some insight 
into the role of chemerin–CMKLR1 or chemerin–GPR1 
axis in coordinating glucose-induced insulin secretion, 
the precise mechanisms are still not clear.
Targeting insulin resistance
Chemerin has also been reported to regulate insulin 
sensitivity and glucose uptake (Table 1). It is conflicting 
that in vitro studies using 3T3-L1 adipocytes provide 
data for both promotive (Takahashi  et  al. 2008) and 
inhibitory (Kralisch  et  al. 2009) effects of chemerin 
on glucose uptake. The different dosages, durations of 
chemerin treatment and culture conditions may cause 
the discrepancy. In the skeletal muscle cells, chemerin 
administration inhibits the insulin-stimulated glucose 
uptake and increases the phosphorylation of insulin 
receptor substrate 1 (Sell  et  al. 2009). Another in vivo 
study shows that chemerin application exacerbates the 
glucose intolerance in different mouse models of obesity 
or diabetes but has no effect on normal lean mice. This 
study shows that chemerin, upregulated in obesity and 
diabetes, specifically reduces the glucose uptake by liver 
but not adipose tissue or skeletal muscle (Ernst et al. 2010).
Notably, all of chemerin, CMKLR1 and GPR1 
mutant mice display glucose intolerance. Chemerin-
knockout mice exhibit impaired insulin sensitivity in 
adipose tissue and liver, resulting in the elevated hepatic 
glucose production, reduced glucose uptake by fat and 
Table 1 Summary of the role of chemerin in glucose metabolism.
 
 
Experimental models
Phenotype  
 
Reference
 
Glucose level
Fasting 
insulin
Glucose-stimulated 
insulin release
Insulin-stimulated 
glucose uptake
Glucose 
production
Chemerin-knockout 
mice
Normal fasting 
glucose; impaired 
glucose tolerance
N.A. Reduced Enhanced muscle 
glucose uptake
Normal basal 
glucose 
production, 
increased 
clamped 
glucose 
production
Takahashi et al. 
(2011)
Chemerin 
overexpression 
transgenic mice
Improved glucose 
tolerance
N.A. Enhanced N.A. N.A. Takahashi et al. 
(2011)
CMKLR1-knockout 
mice
Reduced fasting 
glucose under HFD 
condition; 
impaired glucose 
tolerance
Lower 
under 
HFD 
condition
Reduced Reduced WAT and 
muscle glucose 
uptake
N.A. Ernst et al. (2012)
CMKLR1-knockout 
mice
Normal fasting 
glucose and 
normal glucose 
tolerance under 
HFD condition
Normal N.A. N.A. N.A. Gruben et al. 
(2014)
GPR1-knockout mice Normal fasting 
glucose; impaired 
glucose tolerance 
under HFD 
condition
Lower 
under 
HFD 
condition
Reduced Normal Increased Rourke et al. 
(2014)
Chemerin application 
in mice
Exacerbated glucose 
intolerance in  
ob/ob,  
db/db and HFD 
mice
N.A. Reduced in in 
ob/ob, db/db 
and HFD mice
Reduced liver 
glucose uptake in 
db/db mice
N.A. Ernst et al. (2010)
Chemerin application 
in 3T3-L1 cells
N.A. N.A N.A. Increased N.A. Takahashi et al. 
(2008)
Chemerin application 
in 3T3-L1 cells
N.A. N.A N.A. Reduced N.A. Kralisch et al. 
(2009)
Chemerin application 
in skeletal muscle 
cells
N.A. 
 
N.A 
 
N.A. 
 
Reduced 
 
N.A. 
 
Sell et al. (2009) 
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increased blood glucose level (Takahashi  et  al. 2011). 
Genetic deletion of CMKLR1 in mice leads to reduced 
glucose uptake by adipose tissue and skeletal muscle but 
not liver (Ernst et al. 2012). Under high-fat diet feeding, 
loss of CMKLR1 exacerbates the glucose intolerance, 
increases insulin level and enhances insulin resistance 
in mice (Huang  et  al. 2016). Consistently, heterozygous 
and homozygous Gpr1-knockout mice fed with high-
fat diet develop severe glucose intolerance but exhibit 
reduced glucose-stimulated insulin level (Rourke  et  al. 
2014). Overall, the blood glucose levels are elevated in 
these mutant mice. However, the underlying mechanisms 
remain to be explored. In contradiction to these results, 
another study demonstrated that CMKLR1 deficiency in 
mice did not change body weight, food intake, serum 
lipid level or insulin resistance (Gruben et al. 2014). Thus, 
the role of chemerin signalling in glucose intolerance 
needs to be validated.
Targeting hepatic gluconeogenesis
Gluconeogenesis, a metabolic pathway resulting in the 
generation of glucose from non-carbohydrate carbon 
substrates, takes place mainly in liver. Despite that the 
liver weight and histology are not changed in chemerin-
null mice, the main regulators of gluconeogenesis 
including glucose-6-phosphatase, phosphoenolpyruvate 
carboxylase and transcriptional coactivatior PGC-
1α are upregulated by genetic ablation of chemerin 
(Takahashi  et  al. 2011). As a result, the clamp hepatic 
glucose production is significantly increased in chemerin-
null mice, suggesting that loss of chemerin impairs insulin 
suppression of hepatic glucose generation.
Further analyses in the Cmklr1-knockout mice reveal 
that loss of chemerin signalling reduces the mRNA 
expression of proinflammatory cytokines TNFα and IL-1β 
in the liver, regardless of age or diet (Ernst  et  al. 2012, 
Gruben  et  al. 2014). Interestingly, CMKLR1 loss alters 
immune cell infiltration in the livers of mice fed with low-
fat but not high-fat diet. Consequently, CMKLR1 deficiency 
protects against hepatic steatosis in the mice fed with 
low-fat diet. These results imply that chemerin–CMKLR1 
signalling is indeed involved in hepatic inflammation but 
does not change liver histology. Whether CMKLR1 loss 
impairs gluconeogenesis requires further study.
The association of chemerin with metabolic 
disease in humans
Elevated circulating chemerin is a significant factor for 
metabolic syndrome. It is hypothesised that chemerin 
is multidimensionally involved in the pathogenesis of 
metabolic syndrome by regulating metainflammation, 
adipocyte plasticity and glucose metabolism in humans. 
The correlation between chemerin and obesity/diabetes/
hypertension seems to be well established. Chemerin 
has also been associated with many other diseases, 
including psoriasis, cardiovascular disease and cancer 
(Fig. 4), reviewed in detail elsewhere (Booth  et al. 2015, 
Chiricozzi et al. 2016, İnci et al. 2016).
Obesity
A number of human data indicate that systemic 
chemerin is elevated in obesity. There is a significant 
and positive correlation between chemerin level 
and BMI, waist-hip ratio, waist circumference or 
visceral adipose tissue mass (Bozaoglu  et  al. 2007, 
Chakaroun  et al. 2012, Landgraf  et al. 2012, Shin  et al. 
2012), implying that visceral fat tissue is the primary 
source for circulating chemerin. A further study shows 
that the release of chemerin from adipose tissue explants 
from obese individuals is higher than that in normal-
weight controls, and the amount of secretion is linearly 
correlated with BMI, waist-hip ratio and fat cell volume 
(Sell et al. 2009). Consistent with these studies, systemic 
chemerin is decreased correspondingly in obese patients 
who underwent weight loss by diet intervention or 
bariatric surgery (Sell et al. 2010, Chakaroun et al. 2012). 
Interestingly, weight loss by exercise decreases systemic 
chemerin levels even further, implying that chemerin 
is a strong predictor for change in insulin resistance in 
obese adults (Chakaroun  et  al. 2012, Khoo  et  al. 2015, 
Faramarzi  et  al. 2016). A recent study indicates that 
exercise alone in elderly, independent of weight loss, has 
a beneficial effect on chemerin levels (Kim et al. 2018).
Although the CMKLR1 mRNA level in fat tissue is not 
changed by obesity, the local RARRES2 mRNA expression 
in visceral and subcutaneous adipose tissue is significantly 
increased in obese individuals (Chakaroun et al. 2012). It 
is chemerin expression in omental but not subcutaneous 
fat tissue that contributes to the elevated systemic 
chemerin. With the development of ELISAs targeting the 
four different isoforms of chemerin, it is found that more 
C-terminal processing of chemerin occurs in adipose 
tissue of obese patients, resulting in the higher level of 
bioactive chemerin in local tissue and circulating system 
(Chang  et al. 2016). Obese patients are at increased risk 
of developing numerous comorbid conditions, and 
increased chemerin levels have been linked to many of 
these diseases (Fig. 4).
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Diabetes
Recently, novel adipokines such as vaspin, omentin, 
retinal-binding protein-4, fibroblast growth factor 21, 
adipocyte fatty acid-binding protein and dipeptidyl 
peptidase 4 were found to associate with insulin resistance 
and T2DB in humans (Bergmann & Sypniewska 2013). 
A collection of clinical studies have also investigated 
the correlation between chemerin levels and diabetes. 
While systemic chemerin in patients with T2DM was 
significantly elevated compared to normal-weight controls 
in the Caucasian population (Weigert et al. 2010), it was 
not changed or even reduced in Asian T2DM patients 
without other metabolic complications (Yang et al. 2010, 
Takahashi  et  al. 2013). Importantly, a prospective study 
shows that the elevation of systemic chemerin precedes 
the onset of T2DM (Bobbert et al. 2015), suggesting that 
chemerin could serve as a biomarker for early diagnosis 
of T2DM. Regardless of racial difference, linear regression 
analyses further reveal a cross-sectional correlation 
between systemic chemerin in T2DM patients and age, 
BMI, waist-hip ratio, triglyceride, HOMA-IR, HbA1c, 2-h 
plasma glucose or blood pressure (Weigert  et  al. 2010, 
Yang  et  al. 2010, Bobbert  et  al. 2015). The elevation 
of systemic and local chemerin in adipose tissue is 
strikingly exacerbated in obese individuals with T2DM 
(Bozaoglu et al. 2009, Sell et al. 2010, Chakaroun et al. 2012). 
However, the correlation between circulating chemerin 
and gestational diabetes mellitus has hitherto remained 
very controversial (Bozaoglu et al. 2009, Hare et al. 2014, 
Guelfi et al. 2017, Yang et al. 2017). Together, the systemic 
and local chemerin seems to be upregulated in T2DM 
patients, especially those with metabolic syndrome.
Hypertension
Hypertension is recognised as an important constituent 
of metabolic syndrome. Patients with hypertension have 
significantly higher levels of serum chemerin (Yang et al. 
2010, Gu  et  al. 2014). Despite the potential association 
of chemerin with metabolic characteristics, high 
chemerin level can serve as an independent predictor of 
hypertension after adjustment for metabolic risk factors 
in humans (Gu et al. 2014). As abnormal vascular smooth 
muscle contractility is a major cause of hypertension, 
chemerin may act on CMKLR1 to mediate vasoconstriction 
or promote the proliferation of vascular smooth muscle 
cells (Kunimoto et al. 2015, Kennedy et al. 2016). A recent 
study further reveals that chemerin functions through Gi 
Figure 4
The involvement of chemerin in human diseases. Chemerin is associated with metabolic processes and inflammation and thus its dysregulation plays a 
critical role in human pathophysiology. Chemerin has hitherto been linked with obesity, diabetes, hypertension, psoriasis, lung disease, renal 
dysfunction, arthrosis and cardiovascular, gastrointestinal and reproductive disease.
This work is licensed under a Creative Commons 
Attribution 4.0 Unported License.https://doi.org/10.1530/JOE-18-0174
http://joe.endocrinology-journals.org © 2018 The authors
Published by Bioscientifica Ltd.
Printed in Great Britain Downloaded from Bioscientifica.com at 06/05/2019 11:32:48AM
via free access
R90Chemerin in energy balance 
regulation
G Helfer and Q-F Wu 238:2Journal of 
Endocrinology
proteins to activate L-type Ca2+ channel and elicits a dose-
dependent calcium influx in vascular smooth muscle 
cells, which underlies chemerin-induced vasocontraction 
and hypertension (Ferland  et  al. 2017). A pyridine 
derivative, Y27632, was found to target a Rho-associated 
protein kinase (ROCK) and suppress ROCK-mediated 
Ca2+ sensitisation (Uehata  et  al. 1997). Coinciding with 
the finding that chemerin signals through RhoA/ROCK 
pathway, ROCK inhibitor Y27632 abolishes chemerin-
induced calcium influx and isometric contraction of 
smooth muscle cells (Rourke  et  al. 2015, Ferland  et  al. 
2017). Therefore, upregulation of serum chemerin could 
result in the vasocontraction via ROCK activation and 
Ca2+ sensitisation in vascular smooth muscle cells.
Conclusion
Adipokines have recently emerged as potential regulators 
of appetite and energy homeostasis through endocrine/
systemic action in the brain. Circulating levels of 
adipokines are known to change with increased adiposity 
and are therefore recognised as contributing factor to 
the metabolic changes that are seen in obesity and lead 
to the development of T2DM. One mechanism by which 
adipokines contribute to T2DM is through inflammation-
mediated insulin resistance. As an inflammatory chemokine 
and adipokine, chemerin has been hypothesised as a link 
between obesity and the development of T2DM (Ernst & 
Sinal 2010). Targeting chemerin–CMKLR1 signalling may 
therefore hold therapeutic potential to improve insulin 
signalling in T2DM.
Potential therapeutic role in obesity
Sequence analysis revealed a PPARγ response element within 
the chemerin (RARRES2) promoter (Muruganandan  et  al. 
2011); thus, insulin-sensitising drugs that activate PPARγ 
might be beneficial for the treatment of obesity and T2DM. 
In support, in normal and leptin-deficient ob/ob mice, 
the PPARγ agonist rosiglitazone increased the expression 
of chemerin transcript in adipose tissue and raised plasma 
chemerin level (Muruganandan et al. 2011, Wargent et al. 
2015). However, a human study using antidiabetic drugs 
reported the opposite effect. Pioglitazone and metformin 
decreased plasma chemerin levels in patients with T2DM 
(Esteghamati et al. 2014). It is therefore not clear whether an 
agonist or antagonist of chemerin action might be useful for 
the treatment of T2DM and the contribution of chemerin 
to the pathology of obesity and T2DM remains elusive.
Future research
Collectively, these studies illustrate the complexity of 
chemerin function. Research on this topic is still in its 
infancy and considerably more work is required to clarify 
the mechanisms by which chemerin contributes to obesity 
and associated diseases. Nevertheless, these findings have 
now opened the field to future studies investigating its 
precise biological function. Specifically, the pharmacology 
and signalling properties of chemerin receptors have 
not been characterised in the hypothalamus. Given the 
importance of the hypothalamus in sensing and integrating 
peripheral signals, studies into hypothalamic chemerin 
signalling might help explain some of the contradictory 
results that have been obtained. Furthermore, it is 
important to understand whether chemerin exerts a pro- 
or anti-inflammatory response or if the effect is indeed 
bimodal in different biological systems.
In summary, the exciting findings gathered in the last 
decade clearly highlight an important role for chemerin in 
the regulation of energy balance and makes it a promising 
candidate for urgently needed pharmacological treatment 
strategies for obesity.
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